# Spinraza Clinical Trial Data and Outcomes
Keywords: Spinraza, SMA, Type II SMA, Type III SMA, HFMSE, 6-Minute Walk Test, clinical trials, safety outcomes, motor function

> This page provides information on the clinical trial data and outcomes of Spinraza treatment for 5q SMA, focusing on sustained motor function improvements and safety data over nearly three years.

## Details
- [Natural History of Untreated SMA](#): Overview of disease progression in untreated 5q SMA, highlighting annual declines in HFMSE scores for Type II and Type III SMA.
- [HFMSE Improvements](#): Sustained motor function improvements in patients treated with Spinraza, with specific data for Type II and Type III SMA over 1050 days.
- [HFMSE Scale Description](#): Explanation of the HFMSE scale, detailing scoring criteria and its use in assessing motor function in SMA patients.
- [Study Description](#): Summary of Phase I-II studies CS2 and CS12 evaluating Spinraza's efficacy and safety in SMA patients over a 3-year period.
- [Adverse Event Reporting](#): Guidelines for reporting adverse events in the UK and Ireland, including contact details for Biogen and regulatory authorities.